ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.

ABSTRACT:

Background

Neoantigens can be differentially recognized by T cell receptor (TCR) as these sequences are derived from mutant proteins and are unique to the tumor. The discovery of neoantigens is the first key step for tumor-specific antigen (TSA) based immunotherapy. Based on high-throughput tumor genomic analysis, each missense mutation can potentially give rise to multiple neopeptides, resulting in a vast total number, but only a small percentage of these peptides may achieve immune-dominant status with a given major histocompatibility complex (MHC) class I allele. Specific identification of immunogenic candidate neoantigens is consequently a major challenge. Currently almost all neoantigen prediction tools are based on genomics data.

Results

Here we report the construction

SUBMITTER: Li Y 

PROVIDER: S-EPMC7118832 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature